P/E ratio for Catalent (CTLT)
P/E ratio as of May 2024 (TTM): -43.1
According to Catalent's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -43.1085. At the end of 2022 the company had a P/E ratio of 19.8.
P/E ratio history for Catalent from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 19.8 | -49.36% |
| 2021 | 39.2 | -31.53% |
| 2020 | 57.2 | -13.67% |
| 2019 | 66.2 | 112.43% |
| 2018 | 31.2 | -56.74% |
| 2017 | 72.1 | 97.82% |
| 2016 | 36.4 | 166.37% |
| 2015 | 13.7 | -76.5% |
| 2014 | 58.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | 36.4 | -184.39% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | -77.8 | 80.54% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | -20.3 | -52.83% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | 2.97 | -106.90% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.